CN115317583A - Traditional Chinese medicine composition for postoperative gastric cancer and application thereof - Google Patents

Traditional Chinese medicine composition for postoperative gastric cancer and application thereof Download PDF

Info

Publication number
CN115317583A
CN115317583A CN202210867484.4A CN202210867484A CN115317583A CN 115317583 A CN115317583 A CN 115317583A CN 202210867484 A CN202210867484 A CN 202210867484A CN 115317583 A CN115317583 A CN 115317583A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
gastric cancer
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210867484.4A
Other languages
Chinese (zh)
Other versions
CN115317583B (en
Inventor
李�杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanganmen Hospital of CACMS
Original Assignee
Guanganmen Hospital of CACMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanganmen Hospital of CACMS filed Critical Guanganmen Hospital of CACMS
Priority to CN202210867484.4A priority Critical patent/CN115317583B/en
Publication of CN115317583A publication Critical patent/CN115317583A/en
Application granted granted Critical
Publication of CN115317583B publication Critical patent/CN115317583B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/748—Oldenlandia or Hedyotis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/754—Evodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9062—Alpinia, e.g. red ginger or galangal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine composition used after gastric cancer operation and application thereof, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 30 to 60 parts of raw astragalus root, 15 to 30 parts of radix codonopsitis, 6 to 9 parts of zedoary, 10 to 15 parts of angelica dahurica, 10 to 15 parts of nard, 6 to 9 parts of rhizoma paridis, 10 to 15 parts of giant knotweed rhizome and 15 to 30 parts of Chinese actinidia root. The traditional Chinese medicine composition has scientific and reasonable formula, has the effects of tonifying qi, warming yang, promoting blood circulation, removing stasis, clearing heat and removing toxicity, has certain advantages in the aspect of preventing and treating postoperative recurrence and metastasis of gastric cancer, and can effectively improve uncomfortable symptoms and improve the life quality of patients.

Description

Traditional Chinese medicine composition for postoperative gastric cancer and application thereof
Technical Field
The invention relates to the field of traditional Chinese medicine. More particularly, relates to a traditional Chinese medicine composition used after gastric cancer operation and application thereof.
Background
Gastric cancer is a common digestive tract malignant tumor in China, the number of new gastric cancer cases is about 108.9 ten thousand in 2020 worldwide, china accounts for about 43.9%, the coarse incidence rate of the gastric cancer in 2019 in China is increased from 30.5/10 ten thousand in 2000 to 43.1/10 ten thousand, and the health of Chinese residents is seriously threatened. Surgical resection is the preferred treatment method for gastric cancer, and except 30 to 40 percent of patients with advanced gastric cancer have no surgical chance, the rest patients can be treated by surgery. Although the recurrence rate after the early-stage gastric cancer operation is relatively low, the postoperative recurrence rate of the early-stage gastric cancer patient who receives endoscopic submucosal dissection also reaches about 12.56 percent; and the postoperative recurrence rate of the advanced gastric cancer patients is high and reaches 50-80%, the recurrence appears in 3 years after the operation, the median recurrence time is about 16.8 months, and the survival rate is less than 30% in 5 years after the operation. On the other hand, the changes of the esophageal-gastric-intestinal anatomical structure after the gastric cancer operation lead to the occurrence of a plurality of postoperative complications, the gastric hypomotility occurs, or symptoms such as hypodynamia, nausea, vomiting, acid regurgitation, heartburn, abdominal pain, constipation, abdominal distension, insomnia, short breath and the like are generated due to the postoperative recovery failure and the complication of stomatitis, intestinal obstruction and the like. The occurrence of postoperative complications brings uncomfortable symptoms to the patient after the gastric cancer operation, and the life quality of the patient is seriously affected. At present, the prevention and treatment of postoperative recurrence and metastasis of western medicine are mainly assisted chemoradiotherapy, but chemotherapy aggravates uncomfortable symptoms of patients, influences the life quality of the patients and ensures that the curative effect is not satisfied.
With the continuous and deep research of the traditional Chinese medicine for preventing and treating the gastric cancer, the characteristics and the advantages of the traditional Chinese medicine are widely concerned, a large number of clinical research observations show that the traditional Chinese medicine has advantages in preventing and treating postoperative recurrence and metastasis of the gastric cancer, improving discomfort symptoms, improving the quality of life and the like, and the comprehensive treatment participated in the traditional Chinese medicine is the advantages and the important characteristics of the traditional Chinese medicine for treating the gastric cancer.
Traditional Chinese medicine focuses on holism concept, and the whole state of the organism is corrected by adjusting yin-yang balance, so that the disease resistance of the organism is enhanced, the traditional Chinese medicine compound has multiple target points and the effect of overall regulation in treatment, and has great potential and needs to be further developed. In recent years, most of the traditional Chinese medicine researches on tumors focus on screening medicines with effective components, and development and innovation on traditional Chinese medicine compound effect researches are not deep enough. The traditional Chinese medicine differentiation treatment is guided by the overall view, the core pathogenesis causes the internal environment imbalance of the patient, the pathological process is further caused to cause relapse and transfer, uncomfortable symptoms appear, and the life quality and the long-term prognosis of the patient are influenced. Therefore, the development of a traditional Chinese medicine composition which can effectively prevent and treat postoperative recurrence and metastasis of gastric cancer and can improve the relevant symptoms of gastric cancer patients is needed.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition used after gastric cancer operation, which can be used for distinguishing and treating patients after gastric cancer operation with yang deficiency and toxin accumulation, preventing and treating recurrence and metastasis of gastric cancer after operation, improving postoperative symptoms of patients, improving life quality of patients and prolonging life cycle of patients.
The invention also aims to provide application of the traditional Chinese medicine composition.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a traditional Chinese medicine composition for treating gastric cancer postoperation, which comprises the following raw material medicines in parts by weight: 30 to 60 parts of raw astragalus root, 15 to 30 parts of radix codonopsitis, 6 to 9 parts of zedoary, 10 to 15 parts of angelica dahurica, 10 to 15 parts of nard, 6 to 9 parts of rhizoma paridis, 10 to 15 parts of giant knotweed rhizome and 15 to 30 parts of Chinese actinidia root.
Based on the theory of ' yang qi transformation and yin formation ' in the Suwen and the Binyang corresponding elephant theory ', the invention considers that the formation of tumor is related to ' yang qi transformation is insufficient ' and ' yin formation is too excessive ', so that a patient after gastric cancer operation should strengthen yang to eliminate pathogenic factors, block transmission and prevent yin reformation in the rehabilitation stage. The patients with tumor have yang deficiency, and the cancer-toxin drugs are induced by the combination of toxic and pulsation during treatment, which are both causal.
For people with easy metastasis and recurrence of postoperative yang-deficiency and qi-deficiency of gastric cancer, the yang-deficiency toxin knot is proposed to be the core pathogenesis of postoperative gastric cancer, and the traditional Chinese medicine composition is formed on the basis of a method for deeply strengthening the body resistance and detoxifying to prevent recurrence and metastasis of postoperative gastric cancer.
In the prescription, the raw astragalus root is sweet in taste and slightly warm in nature, enters lung and spleen channels, is yellow in color, enters spleen and stomach, has the effects of tonifying qi and yang, activating stagnancy and relieving arthralgia, is gasified by innate fire and soil, and mainly tonifies deficiency, so the prescription is named as' rising yang and also 82308230, has the effects of warming meat and strengthening skin striae, tonifying primordial qi and three-jiao, internally supporting pyocutaneous disease of yin deficiency syndrome, externally reinforcing night sweat of exterior deficiency, strengthening body resistance to eliminate pathogenic factors, tonifying yang to eliminate yin, self-declining healthy qi, and especially for postoperative yang qi deficiency syndrome of stomach cancer, and is a monarch drug.
Dangshen is sweet in taste, neutral in nature, enters spleen and lung channels, and well enters spleen and stomach to reinforce middle-jiao energy, the theory of compendium of materia medica says that the spleen and stomach are good at 8230, the middle-jiao energy is weak, the spleen and stomach are good at regulating and tonifying, the spleen and stomach invigorate yang, the middle-jiao energy is stimulated, the spleen and stomach are transported without dryness, the stomach yin is nourished without dampness, the lung fluid is moistened without cold, the qi and blood are nourished without greasiness, the sex is well nourished without the defect of dryness, the dangshen is a product for warming middle-jiao and tonifying qi together with astragalus, the formula of matching herbs is called that astragalus is obtained, the health is kept, the two are combined, the middle-jiao and yang is strengthened, the foundation is cleared, and the origin is cleared, and the stomach cancer postoperative spontaneous perspiration and emaciation has good improvement effect on yang deficiency and emaciation.
Zedoary, pungent and bitter in flavor and warm in nature, entering liver and spleen meridians, good at moving qi and breaking blood, resolving food stagnation and relieving pain, breaking blood in qi and promoting blood circulation and qi coagulation, is called as ' appetizing and promoting digestion, breaking accumulation, moving blood stasis and treating heart pain and removing abdominal pain ' in the book of property of medicine ' and is a special medicine for removing food stagnation, matched with codonopsis pilosula, tonifying middle-jiao and reducing diarrhea, and combining moving and static medicines, which are ministerial medicines together.
The nard is sweet and pungent in flavor, sweet in flavor and warm in nature, enters spleen and stomach channels, has the effects of regulating qi to alleviate pain, relieving depression and activating spleen, and is good at dredging yang and resolving stagnation and dissipating stagnation of qi; polygonum cuspidatum is slightly bitter in taste and slightly cold in nature, enters liver, gallbladder and lung channels, has the effects of promoting diuresis, removing jaundice, clearing heat, detoxifying, dissipating blood stasis and relieving pain, is mainly used for treating sore, furuncle and carbuncle, is called as blood stasis breaking syndrome in famous medical records, and is especially good at dissipating blood stasis and relieving cancer toxin; the Chinese actinidia root is bitter in taste and cold in nature, has the effects of clearing heat, promoting diuresis, detoxifying, activating blood, reducing swelling and resisting cancer; paris polyphylla, bitter in taste and slightly cold in nature, enters liver meridian, has the effects of clearing heat and detoxicating, and relieving swelling and pain, and can be used for treating furuncle, carbuncle and swelling, and sore throat. The giant knotweed rhizome, the Chinese actinidia root and the rhizoma paridis are mutually reinforced, and have the effects of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, resisting cancer and softening hard masses. The nardostachys root and rhizome, rhizoma Polygoni Cuspidati, radix Actinidiae chinensis and rhizoma paridis are compatible, can regulate qi, remove blood stasis without channeling, clear away heat and toxic materials without cold stagnation, use cold and heat in combination, and reversely flow back and forth, and are used as adjuvant drugs to regulate the qi movement of middle energizer to ascend and descend.
The angelica dahurica has pungent taste, warm nature, light smell, and belongs to the stomach, large intestine and lung channels, has the effects of warming the middle-jiao, stimulating the appetite, dissipating dirt, promoting the growth of qi in spring, promoting the pus discharge, supporting sore, promoting tissue regeneration, promoting granulation, restoring menstrual flow and benefiting orifices, is a medicament for drawing channels of the stomach channel for improving yang, is also a whole prescription of a messenger medicament, has good improvement on gastric cavity and abdominal cavity fright after gastric cancer operation, and has the effects of warming yang and resisting cancers.
The whole formula has the effects of tonifying qi, warming yang, promoting blood circulation, removing stasis, clearing heat and removing toxicity, performing both reinforcement and purgation, combining cold and heat, combining defense and offensive, and reversing reverse, and is particularly good for patients with postoperation yang deficiency of gastric cancer.
The traditional Chinese medicine composition is designed according to the formula principle, gives consideration to diseases, symptoms and symptoms, aims at relieving symptoms such as chilly, hypodynamia, anorexia, emaciation, abdominal distension, abdominal pain, constipation and the like aiming at the symptoms of yang deficiency and toxin accumulation of the gastric cancer, and belongs to the core prescription for postoperative syndrome differentiation of the gastric cancer. The traditional Chinese medicine composition is clinically used for syndrome differentiation, has the effects of tonifying qi, warming yang, promoting blood circulation, removing stasis, clearing heat and removing toxicity, can control tumor progress, quickly relieves the yang-deficiency and toxicity accumulation symptoms of gastric cancer patients, inhibits relapse and metastasis after gastric cancer operation, promotes symptoms of the gastric cancer patients after the gastric cancer operation to be improved, improves life quality and prolongs survival time.
In the specific embodiment of the invention, the raw material medicaments of the traditional Chinese medicine composition are adjusted on the basis of the traditional Chinese medicine composition according to clinical symptoms:
1) Aiming at the patients with acid regurgitation and heartburn, at least one of 15 to 30 parts of calcined concha arcae, 6 to 9 parts of coptis and 3 to 6 parts of fructus evodiae is added;
2) Aiming at patients with hiccup nausea and vomiting, at least one of 10 to 15 parts of inula flower, 10 to 15 parts of ruddle, 10 to 12 parts of wrinkled gianthyssop herb and 10 to 15 parts of cogongrass rhizome is added;
3) Aiming at abdominal pain and abdominal distension, at least one of 10 to 15 parts of fried bitter orange, 10 to 15 parts of radish seed, 10 to 15 parts of magnolia officinalis, 10 to 15 parts of white peony root and 15 to 30 parts of raw coix seed is added;
4) Aiming at poor appetite, at least one of 15 to 20 parts of yam, 15 to 20 parts of tuckahoe, 6 to 12 parts of liquorice, 15 to 30 parts of raw malt and 15 to 30 parts of endothelium corneum gigeriae galli is added;
5) Aiming at patients with short breath and fatigue and weakness, at least one of 30 to 40 parts of raw astragalus, 10 to 20 parts of fried bighead atractylodes rhizome, 6 to 9 parts of rhizoma anemarrhenae, 6 to 9 parts of rhizoma cimicifugae and 6 to 9 parts of platycodon grandiflorum is added;
6) Aiming at the people who are aversion to cold, at least one of 6 to 9 parts of dried ginger, 3 to 5 parts of cassia twig, 10 to 15 parts of cistanche and 10 to 15 parts of eucommia bark is added;
7) Aiming at insomnia and dreaminess patients, at least one of 10-15 parts of cortex albiziae, 30-45 parts of mother-of-pearl, 15-30 parts of tuber fleeceflower stem, 30-45 parts of fried jujube kernel and 12-30 parts of fructus alpiniae oxyphyllae is added;
8) Aiming at the limbs anesthesia, at least one of 9 to 15 parts of red paeony root, 6 to 15 parts of cassia twig, 10 to 20 parts of mulberry twig, 10 to 20 parts of common clubmoss herb and 10 to 20 parts of achyranthes bidentata is added;
9) Aiming at epigastric pain, at least one of 10-20 parts of herba ecliptae, 10-20 parts of glossy privet fruit, 10-20 parts of sedum sarmentosum, 10-20 parts of charred madder, 10-15 parts of raw cattail pollen and 10-20 parts of spreading hedyotis herb is added.
The above regulating formula can be selected from any one or combination of more of the above regulating formulas according to different symptoms to achieve the purpose of controlling the recurrence and metastasis of gastric cancer.
In a second aspect, the invention provides a traditional Chinese medicine preparation, which is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
The dosage form of the traditional Chinese medicine preparation comprises tablets, granules, pills, powder, paste, capsules, medicinal granules or powder.
According to the preparation method of the traditional Chinese medicine preparation in the field, the effective components in the raw material medicines are extracted and refined according to the conventional method of the traditional Chinese medicine preparation in the field, and then the traditional Chinese medicine preparation is prepared into pills, capsules, tablets, powder, oral liquid or granules and other dosage forms, or can be directly decocted in water and taken as decoction. Experiments prove that the preparation method and the using method can achieve the treatment effect of the medicine.
In a third aspect, the invention provides an application of a traditional Chinese medicine composition used after gastric cancer surgery in preparing any one of the following medicines;
1) Medicine for preventing and treating postoperative recurrence and metastasis of gastric cancer;
2) A medicament for improving clinical symptoms of a patient after gastric cancer surgery, wherein the clinical symptoms comprise at least one of aversion to cold, fatigue, anorexia, emaciation, gastroesophageal reflux, abdominal distension, abdominal pain, diarrhea, constipation and dumping syndrome;
3) Medicine for improving the life quality of patients after gastric cancer operation.
In addition, unless otherwise specified, all the raw materials of the Chinese medicinal composition can be commercially available, and the Chinese medicinal composition in any range including any value between the endpoints and any sub-range composed of any value between the endpoints or any value between the endpoints can achieve the purpose of controlling gastric cancer.
The invention has the following beneficial effects:
clinical tests prove that the traditional Chinese medicine composition can effectively prevent and treat postoperative recurrence and metastasis of gastric cancer, and specifically, the postoperative recurrence and metastasis rate of the gastric cancer is only 21.70% after 2 years of treatment by the traditional Chinese medicine composition, and the effect is remarkably superior to that of the traditional Chinese and Western medicine treatment methods.
Clinical tests prove that the traditional Chinese medicine composition can improve postoperative symptoms of patients and improve the life quality of the patients, and has good medicine safety. Specifically, the traditional Chinese medicine composition has remarkable effects on the aspects of treating postoperative gastroesophageal reflux symptoms, abdominal pain, eating-related troubles, dyspepsia, diarrhea, constipation, dumping syndrome and the like of patients.
The traditional Chinese medicine composition is mainly based on syndrome differentiation, analyzes the etiology, pathogenesis, disease nature and disease position of the current stage of the disease according to the symptoms and signs of the disease, combines the pharmacological research of modern traditional Chinese medicines on the basis of taking the prescription based on syndrome differentiation, adopts a disease and symptom combination method, and simultaneously gives consideration to symptom treatment, thereby achieving remarkable curative effect and presenting the most rational treatment strategy.
Detailed Description
In order to illustrate the invention more clearly, the invention is further described below with reference to preferred examples and statistical data. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example 1A traditional Chinese medicine composition for post-operation of gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 30g of raw astragalus, 15g of codonopsis pilosula, 6g of curcuma zedoary, 10g of angelica dahurica, 10g of nardostachys root, 6g of paris polyphylla, 10g of polygonum cuspidatum and 15g of actinidia chinensis.
Example 2A traditional Chinese medicine composition for post-operation of gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 60g of raw astragalus, 30g of codonopsis pilosula, 9g of curcuma zedoary, 15g of angelica dahurica, 15g of nard, 9g of rhizoma paridis, 15g of polygonum cuspidatum and 30g of Chinese actinidia root.
Example 3A traditional Chinese medicine composition for post-operation of gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 45g of raw astragalus, 20g of codonopsis pilosula, 9g of curcuma zedoary, 12g of angelica dahurica, 12g of nard, 6g of rhizoma paridis, 12g of polygonum cuspidatum and 20g of actinidia chinensis.
Example 4A Chinese medicinal composition for use after gastric cancer surgery
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 30g of raw astragalus, 15g of codonopsis pilosula, 6g of curcuma zedoary, 15g of angelica dahurica, 15g of nardostachys root, 9g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of actinidia root, 30g of calcined concha arcae, 6g of coptis and 3g of fructus evodiae.
Example 5A traditional Chinese medicine composition for post-operation of gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 45g of raw astragalus, 30g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 15g of nard, 9g of rhizoma paridis, 15g of polygonum cuspidatum, 30g of Chinese actinidia root, 15g of inula flower, 15g of ruddle, 12g of agastache rugosus and 15g of lalang grass rhizome.
Example 6A traditional Chinese medicine composition for post-operation gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 30g of raw astragalus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nard, 6g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of Chinese actinidia root, 10g of fried fructus aurantii, 15g of radish seed, 10g of mangnolia officinalis, 15g of white peony root and 30g of raw coix seed.
Example 7A Chinese medicinal composition for use after gastric cancer surgery
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 45g of raw astragalus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nard, 6g of rhizoma paridis, 15g of polygonum cuspidatum, 30g of actinidia chinensis root, 30g of raw malt, 15g of endothelium corneum gigeriae galli, 15g of fried bighead atractylodes rhizome, 20g of Chinese yam, 15g of poria cocos, 6g of liquorice, 9g of rhizoma anemarrhenae, 6g of cimicifugae foetidae and 6g of platycodon grandiflorum.
Example 8A traditional Chinese medicine composition for post-operation gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 45g of raw astragalus, 30g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nard, 6g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of actinidia chinensis root, 9g of rhizoma zingiberis, 3g of cassia twig, 15g of cistanche, 15g of eucommia, 15g of cortex albiziae, 30g of mother-of-pearl, 15g of tuber fleeceflower stem, 30g of fried jujube kernel and 15g of fructus alpiniae oxyphyllae.
Example 9A traditional Chinese medicine composition for post-operation gastric cancer
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 30g of raw astragalus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nard, 6g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of Chinese actinidia root, 9g of red paeony root, 6g of cassia twig, 10g of mulberry twig, 10g of lycopodium clavatum and 20g of achyranthes bidentata.
Example 10A Chinese medicinal composition for use after gastric cancer surgery
A traditional Chinese medicine composition for treating gastric cancer comprises the following raw material medicines: 30g of raw astragalus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nard, 6g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of Chinese actinidia root, 15g of eclipta, 15g of glossy privet fruit, 15g of sedum sarmentosum, 12g of carbonized madder, 10g of raw cattail pollen and 15g of oldenlandia diffusa.
The first study is as follows: intervention study on relapse and metastasis of gastric cancer postoperative patient
1. Research design: in 2016, 9-2022, 03, 106 patients were diagnosed in outpatients of oncology department in Guangan Hospital, chinese academy of traditional Chinese medicine, and 106 patients who had not developed recurrence and metastasis after standard radical gastric cancer therapy of traditional Chinese medicine treatment according to AJCC 2016, 8 th edition of TNM staging at cT2-4NxM 0. 74 men and 32 women among the above cases; the age is 36-88 years; 21 cases of cardia, 26 cases of stomach body and 59 cases of antrum of stomach at the tumor occurrence position; the pathological typing mainly comprises adenocarcinoma 101 cases, mucus adenocarcinoma 3 cases and signet ring cell carcinoma 2 cases; degree of tissue differentiation: 59 cases of low differentiation, 22 cases of medium and low differentiation, 15 cases of medium differentiation, and 5 cases of high and medium differentiation; in pathological stages, there are 5 cases of IB, 13 cases of IIA, 24 cases of IIB, 26 cases of IIIA, 23 cases of IIIB and 15 cases of IIIC. All patients are clinically diagnosed definitely, after entering the group, according to the principle of combining diseases, symptoms and symptoms, the traditional Chinese medicine composition of the embodiment 1 of the invention is adopted as the main formula, the accumulated treatment time of the traditional Chinese medicine is not less than 6 months, and other medicines which possibly have treatment effects on tumors cannot be applied in a combined way during the administration period. The recurrence and metastasis rates (stump/anastomotic stoma recurrence, organ metastasis and lymph node metastasis) are accumulated for 6 months, 12 months, 18 months and 24 months after the operation according to the auxiliary examination such as the reexamination imaging examination, the gastroscope pathology, the tumor marker and the like, and the results are compared and analyzed.
2. The research results are as follows: of the 106 patients, 26 had recurrent metastases. The patient with the earliest recurrence of metastasis was found 5 months after surgery, and the patient with the longest recurrence was 34 months after surgery. 1 case of recurrent metastasis within 6 months after surgery; after the operation, 5 cases of recurrent metastasis occur within 6-12 months, and 6 cases are accumulated; 6 cases of recurrence and metastasis occur within 12-18 months after operation, and 12 cases are accumulated; there were 11 cases of recurrent metastasis within 18-24 months after surgery, and 23 cases were accumulated. The recurrence and metastasis rates of patients after gastric cancer surgery were 0.94%, 5.66%, 11.32% and 21.70% at 6 months (0.5 year), 12 months (1 year), 18 months (1.5 years) and 24 months (2 years), respectively, as shown in table 1.
TABLE 1 relapsing metastatic disease
Time Number of examples Recurrence and metastasis rate
Postoperative 0.5 years (6 months) 1 0.94％
Postoperative 1 year (12 months) 6 5.66％
After operation within 1.5 years (18 months) 12 11.32％
Postoperative 2 years (24 months) 23 21.70％
3. And (4) analyzing results: reviewing the previous literature research, there are studies reviewing 232 patients after radical gastric cancer treatment, the clinical data shows that the number of male and female is 2.89, the tnm stage i: ii: iii is 1. The results of the study showed that the median recurrence and metastasis time after radical gastric carcinoma treatment was 17.3 months (95% ci: analysis of influence factors of early recurrence and metastasis after gastric carcinoma radical treatment [ J ] analysis of oncology journal 2020,26 (12): 1052-1055 ]. Meta analysis shows that the recurrence rates of the traditional Chinese and western medicine comprehensive treatment for 12 months, 24 months and 36 months after gastric cancer operation are respectively reduced by 52%, 43% and 47%, and the method is remarkably superior to simple western medicine treatment [ see: the Meta analysis of traditional Chinese medicine combined chemotherapy for preventing postoperative recurrence of gastric cancer [ J ]. J. Hunan J.TCM, 2016,32 (09): 145-147 ]. A random contrast study of traditional Chinese medicine intervention after gastric cancer surgery is characterized by more males, age of 45-75 years, mainly adenocarcinoma as pathology and more stages in III stage, and is basically consistent with the clinical features of the study. Research results show that the combination of chemotherapy with the same treatment prescription for phlegm and blood stasis (pinellia ternate, dried orange peel, arisaema cum bile, edible tulip, salvia miltiorrhiza and the like) can reduce the recurrence and metastasis rate of gastric cancer postoperative for 2 years from 56.67% to 30% (P < 0.05) [ see: mingli, qihong, wanghai bridge, etc. combined treatment of phlegm and blood stasis with chemotherapy for advanced gastric cancer 60 cases of post-operation clinical observation [ J ]. Chinese J.I. and Western J.I. digestion, 2017,25 (07): 481-484]. As no control group is set in the research, the results of the documents show that the traditional Chinese medicine composition can reduce the recurrence and metastasis rate of the patient after the gastric cancer operation to a certain extent, and has more advantageous effects.
Study two: intervention research on survival quality of gastric cancer postoperative patient
1. Research and design: 29 patients after gastric cancer outpatient service in department of oncology of Guangan Men Hospital of Chinese academy of traditional Chinese medicine were diagnosed at 11-2022 years 03 at 2021, and according to 8 th edition IA-IIIA stage of AJCC 2016, KPS score was not less than 70, 27 adenocarcinoma (93.1%), and 2 adenosquamous carcinoma (6.9%), 17 male, 12 female, and 42-89 years old. All patients are clinically diagnosed clearly, and the treatment is evaluated for at least 4 weeks by adopting the traditional Chinese medicine composition of the embodiment 1 as a main formula.
2. The research standard is as follows:
EORTC-QLQ-STO22 and a postoperative gastrotomy syndrome evaluation scale PGSAS-45 are adopted to evaluate the clinical curative effect and the quality of life, and the results are compared and analyzed. Wherein the amount of EORTC-QLQ-STO22 comprises two contents of 5 symptom fields (dysphagia, pain, reflux symptom, limited eating, anxiety) and 4 single symptom items (dry mouth, taste change, body image, alopecia), and each score in each field is 100 points.
The PGSAS-45 post-gastrectomy syndrome assessment Scale includes 8 entries from Short Form Health Surgery (SF-8), 15 entries from the Gastrointestinal Symptom assessment Scale (GSRS), and another 22 entries for 47 surgeons to review questionnaires from 1777 patients to screen out the entry that best responds to the patient's post-gastrectomy symptoms, which can objectively and comprehensively assess the patient's complications, work and life status, and quality of life. PGSAS-45 includes 8 entries for assessing health-related quality of life, 8 entries for eating, 1 entry for work status, 3 entries for reflecting post-operative satisfaction of daily living, 25 entries for post-operative symptoms. Of these, 25 symptom-related items reflect seven aspects of symptoms, including: gastroesophageal reflux symptoms, abdominal pain, eating related disturbances, dyspepsia, diarrhea, constipation, and dumping syndrome. Wherein the items 1-8 and 38-45 are scored by a Likert 5 subscale, and the items 9-28 and 30-32 are scored by a Likert 7 subscale. Can be summarized into 10 main observation indicators: a quality of life subscale, a gastroesophageal reflux symptom subscale, an abdominal pain symptom subscale, a feeding-related discomfort symptom subscale, an dyspepsia symptom subscale, a diarrhea symptom subscale, a constipation symptom subscale, a dumping syndrome subscale, a feeding quality subscale, an under-living subscale.
3. The research results are as follows:
the evaluation results of EORTC-QLQ-STO22 and PGSAS-45 after treatment show (see tables 2-3), the traditional Chinese medicine composition is used as the main formula, and the differences before and after treatment (P is less than 0.05) of patients after treatment in the aspects of dysphagia, pain, limited eating, dry mouth, quality of life, gastroesophageal reflux, abdominal pain, eating-related discomfort, dyspepsia, dumping syndrome, unsatisfied life and the like are significant, so that the traditional Chinese medicine composition has statistical significance, and can effectively improve the common symptoms after gastric cancer operation and improve the quality of life.
TABLE 2 comparison of symptom Domain and symptom item score results for QLQ-STO22 before and after treatment of patients (P25, P75)
Figure BDA0003760000640000091
* Represents P < 0.01 compared to pre-treatment; delta represents P < 0.05 compared to pretreatment
Table 3 comparison of the results of PGSAS-45 gastric cancer observation index scores before and after treatment of patients (score,
Figure BDA0003760000640000092
) Or (P25, P75)
Figure BDA0003760000640000093
Figure BDA0003760000640000101
* Represents P < 0.01 in comparison to pretreatment
And (4) research III: typical cases and efficacy:
case 1 after gastric cancer postoperative chemotherapy, the simple traditional Chinese medicine consolidation treatment improves the long-term survival
Patient, female, 55 years old, 24 days 4 months in 2013 with total stomach-duodenal stump-lower esophageal resection, postoperative pathological indication: poorly differentiated adenocarcinoma of the stomach, penetrating the entire stomach wall to the surrounding adipose tissue; no vascular involvement (-); visible nerve involvement (+); no cancerous tissue (-) is found at the lower esophageal end, the duodenal stump, and the circumferential margin; lymph node cancer metastasis (minor curvature 2/5, major curvature 0/15). pTNM staging: stage IIIA (T3N 1 Mx). Immunohistochemistry: CK7 (-), CK20 (-), P53 (+), ki-67 (+, > 50%), S-100 (nerve +), ERCC-1 (+), TS (+), topll (+, about 30%), her-2 (-), pgp (-). The FOLFOX regimen was followed for 6 cycles of chemotherapy. The first visit is 1 month and 16 days in 2014, and patients complain of hypodynamia, numbness of hands and feet, aversion to cold, sleep, 3-4 times per day of defecation, pale red tongue, thin and white fur, and thready and weak pulse. And (3) Western diagnosis: gastric cancer; traditional Chinese medicine diagnosis: stomach cancer, syndrome of yang deficiency and toxin accumulation. The therapeutic method of traditional Chinese medicine: warming yang, invigorating spleen, removing toxic substance, and resisting cancer. Prescription: 30g of raw astragalus membranaceus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of radix angelicae, 10g of nard, 6g of rhizoma paridis, 10g of polygonum cuspidatum, 15g of Chinese actinidia root, 9g of cassia twig, 15g of Hangzhou white peony root, 15g of mulberry twig, 15g of lycopodium clavatum, 15g of glossy privet fruit, 15g of eclipta, 15g of radix achyranthis bidentatae, 15g of Chinese yam, 15g of radix paeoniae rubra, 15g of sedum sarmentosum, 30g of raw malt, 15g of endothelium corneum gigeriae galli, 6g of liquorice and 15g of oldenlandia diffusa. The 21 dose is decocted in water, one dose is taken every day, and the dose is taken after breakfast and supper.
2, 13 days of re-diagnosis in 2014: after the patient takes the medicine, the numbness of hands and feet and the fear of cold are relieved before the patient feels cold, and the patient can take the medicine for sleep and is convenient to adjust. A pale-red tongue with thin and white coating and a thready and weak pulse. The medicine is taken sequentially with 28 doses and 1 dose/day, and is decocted with water for oral administration, and is taken warm in the morning and evening. The patients are treated at the clinic at the later time, and the treatment is carried out according to the syndrome differentiation of the above prescriptions until now, without postoperative discomfort symptoms.
The follow-up diagnosis is carried out 3 months and 9 days in 2022: nausea, acid regurgitation and heartburn, abdominal distension, numbness of hands and feet after long-time cooling, easy sleep, easy adjustment, hyperhidrosis, dry mouth and bitter taste. The tongue is pale red, the coating is thin and yellow, and the pulse is thready and smooth. Traditional Chinese medicine diagnosis: stomach cancer, syndrome of yang deficiency and toxin accumulation. Considering that the body is lack of nourishment due to yang deficiency and the medicine toxicity is cemented in the body, the symptoms are obviously relieved at first time, and attention is paid to preventing and treating the relapse and the metastasis after the operation, firstly, the medicine is arranged on the place without being affected by the pathogen, the cancer toxicity is dissolved in advance, and then, the yang is warmed, the spleen is strengthened, and the medicine toxicity is detoxified and the cancer is resisted. Prescription: 20g of raw astragalus membranaceus, 10g of codonopsis pilosula, 9g of curcuma zedoary, 12g of angelica dahurica, 12g of nardostachys root, 9g of rhizoma paridis, 15g of polygonum cuspidatum, 15g of Chinese actinidia root, 6g of cassia twig, 15g of radix paeoniae alba, 15g of radix paeoniae rubra, 12g of fructus alpiniae oxyphyllae, 15g of calcined concha arcae, 15g of mulberry twig, 15g of lycopodium clavatum, 10g of fried fructus aurantii, 30g of raw malt, 15g of endothelium corneum gigeriae galli, 6g of liquorice, 15g of oldenlandia diffusa, 15g of lalang grass rhizome. The 21 dose is decocted with water, one dose is taken every day, and the dose is taken after breakfast and supper. The 28 doses are decocted in water for oral dose, one dose is taken every day, and the dose is divided after breakfast and supper. The patient survived for 9 years and had no signs of recurrent metastasis after repeated examinations.
Case 2 after postoperative chemotherapy of gastric cancer, the disease was treated by simple differentiation of symptoms with traditional Chinese medicine, and the disease symptoms were improved and the quality of life was improved
The patient, male, 55 years old, was subjected to cardia cancer resection in 2019 month 1, and postoperative pathology suggested: the elevated cardia type of low differentiation adenocarcinoma, diffuse type, refers to signet ring cell carcinoma, and the lesion invades the mucosa and submucosa. Metastatic cancer was not seen in lymph nodes (0/8), T2N0M0, immunohistochemical results show: EGFR (1 +), MLH1 (+), MSH2 (+), MSH6 (+), PMS2 (+), and then completing the tegafur 8 cycle chemotherapy. The first diagnosis is taken in 7 months in 2019, and patients complain of calmness, acid regurgitation, occasional nausea, no vomiting, poor appetite, occasional dull pain in stomach, obvious pain during hunger, fatigue, poor sleep, dreaminess, easy waking up, dry mouth, bitter taste, dry cough, clear and bright cough sound, yellow urine, unformed stool, sticky texture, shortness of breath in spleen, pale, swollen tongue, white and greasy fur, and wiry and thready pulse. And (3) Western diagnosis: cardiac cancer; traditional Chinese medicine diagnosis: stomach cancer, syndrome of yang deficiency and toxin accumulation. The therapeutic method of traditional Chinese medicine: warming yang, invigorating spleen, removing toxic substance, and resisting cancer. Prescription: 60g of raw astragalus root, 9g of curcuma zedoary, 15g of giant knotweed rhizome, 15g of Chinese actinidia root, 10g of nard, 10g of angelica dahurica, 6g of paris polyphylla, 15g of codonopsis pilosula, 10g of inula flower (wrapped decoction), 15g of carbonized madder, 10g of fried bitter orange, 15g of cortex albiziae, 30g of fried jujube kernel, 30g of nacre (decocted first), 30g of raw malt, 15g of achyranthes bidentata, 15g of chicken's gizzard-membrane, 6g of raw licorice, 15g of oldenlandia diffusa and 15g of calcined flute, 21 doses of water are decocted for taking, one dose is taken every day, and the doses are taken separately after breakfast and supper.
8, 8 and 21 days of repeated diagnosis in 2019: after the patient takes the medicine, the stomach distension and the stomachache are obviously relieved, the patient sometimes has sour regurgitation, sleepiness, bitter taste in the morning, red tongue, thin white greasy coating and wiry and thready pulse. The decoction is decocted with water for oral administration with 28 doses for 1 dose/day, and is taken warm in the morning and evening. After the clinic visit, the patients are treated with the above formula until now, the suprapulmonious nodules of the right lung have no obvious progress, and the postoperative discomfort symptoms are eliminated.
Case 3 after postoperative chemotherapy of gastric cancer, the disease is treated based on syndrome differentiation with traditional Chinese medicine, the symptoms are improved, and the quality of life is improved
Patient, male, 70 years old, and carrying out radical gastric cancer operation in 2020 and 4 months, postoperative pathological indication: gastric ulcer type of medium-low differentiation adenocarcinoma with a size of 3.0 × 2.5 × 1.5cm, invasion of pathological changes into superficial muscle layer, and vascular cancer embolus. Metastatic cancer was seen in lymph nodes (17/20), T2N3M0, stage IIb, followed by completion of 6-cycle XELOX regimen chemotherapy. The first diagnosis is taken in 11 months and 30 days of 2020, patients complain of epigastric psychroalgia, are willing to rub and press, are uncomfortable to eat, have obvious pain during hunger, relieve after eating, have mental fatigue and hypodynamia, sleep, have excessive passing qi, have heavy taste, loose and thin stool easily, 1 row in day, feel incomplete in urination, and urinate for 2-3 times, have pale, dark, fat, white and greasy tongue fur, have tooth marks at the edge, and have wiry pulse. And (3) Western diagnosis: gastric cancer; traditional Chinese medicine diagnosis: stomach cancer, syndrome of yang deficiency and toxin accumulation. The therapeutic method of traditional Chinese medicine: warming yang, invigorating spleen, removing toxic substance, and resisting cancer. Prescription: 30g of raw astragalus, 15g of codonopsis pilosula, 9g of curcuma zedoary, 10g of angelica dahurica, 10g of nardostachys root, 9g of rhizoma paridis, 10g of giant knotweed rhizome, 10g of Chinese actinidia root, 15g of fried bighead atractylodes rhizome, 15g of poria cocos, 10g of raw cattail pollen (decocted by wrapping), 30g of Chinese yam, 30g of raw coix seed, 15g of mulberry twig, 15g of lycopodium clavatum, 15g of sharpleaf galangal fruit, 15g of red paeony root, 10g of fried fructus aurantii, 30g of malt, 15g of chicken's gizzard-membrane, 6g of raw liquorice, 15g of oldenlandia diffusa, 15g of lalang grass rhizome, 10g of magnolia officinalis, 15g of silktree albizzia bark and 15g of tuber fleeceflower stem, 28 doses of water are decocted for taking, and the medicine is taken after one dose is breakfast and dinner. The subjective symptoms improved, and 28 doses were administered locally.
Follow-up visit in 2022, 2, month and 11 days: after the patient takes the medicine, the cold pain in the gastric cavity, the discomfort of eating are obviously relieved, the nocturia is reduced, the bowel sound fails to breathe, the tongue is dark, the tongue coating is white and greasy, and the pulse is wiry. The decoction is decocted with water for oral administration with 28 doses for 1 dose/day, and is taken warm in the morning and evening. After the clinic visit, the patients are treated with the above formula until now, the gastric cancer has not progressed, and the postoperative discomfort symptoms are eliminated.
It should be understood that the above-described embodiments of the present invention are examples for clearly illustrating the invention, and are not to be construed as limiting the embodiments of the present invention, and it will be obvious to those skilled in the art that various changes and modifications can be made on the basis of the above description, and it is not intended to exhaust all embodiments, and obvious changes and modifications can be made on the basis of the technical solutions of the present invention.

Claims (10)

1. A traditional Chinese medicine composition used after gastric cancer operation is characterized by comprising the following raw material medicines in parts by weight: 30 to 60 parts of raw astragalus root, 15 to 30 parts of radix codonopsitis, 6 to 9 parts of zedoary, 10 to 15 parts of angelica dahurica, 10 to 15 parts of nard, 6 to 9 parts of rhizoma paridis, 10 to 15 parts of giant knotweed rhizome and 15 to 30 parts of Chinese actinidia root.
2. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: at least one of 15 to 30 parts of calcined concha arcae, 6 to 9 parts of coptis and 3 to 6 parts of fructus evodiae.
3. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 10 to 15 parts of inula flower, 10 to 15 parts of ruddle, 10 to 12 parts of wrinkled gianthyssop herb and 10 to 15 parts of cogongrass rhizome.
4. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 10 to 15 parts of fried bitter orange, 10 to 15 parts of radish seed, 10 to 15 parts of magnolia officinalis, 10 to 15 parts of white peony root and 15 to 30 parts of raw coix seed.
5. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 15 to 30 parts of yam, 15 to 20 parts of tuckahoe, 6 to 12 parts of liquorice, 15 to 30 parts of raw malt and 15 to 30 parts of endothelium corneum gigeriae galli.
6. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 30 to 40 parts of raw astragalus, 10 to 20 parts of fried white atractylodes rhizome, 6 to 9 parts of rhizoma anemarrhenae, 6 to 9 parts of cimicifuga foetida and 6 to 9 parts of balloonflower root.
7. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 6 to 9 parts of dried ginger, 3 to 5 parts of cassia twig, 10 to 15 parts of cistanche and 10 to 15 parts of eucommia bark.
8. The traditional Chinese medicine composition of claim 1, wherein the bulk drug further comprises: 10 to 15 parts of cortex albiziae, 30 to 45 parts of mother-of-pearl, 15 to 30 parts of tuber fleeceflower stem, 30 to 45 parts of fried jujube kernel and 12 to 30 parts of fructus alpiniae oxyphyllae;
preferably, the bulk drug further comprises: 9 to 15 parts of red peony root, 6 to 15 parts of cassia twig, 10 to 20 parts of mulberry twig, 10 to 20 parts of lycopodium clavatum and 10 to 20 parts of achyranthes bidentata;
preferably, the bulk drug further comprises: 10 to 20 parts of yerbadetajo herb, 10 to 20 parts of glossy privet fruit, 10 to 20 parts of sedum sarmentosum, 10 to 20 parts of India madder root charcoal, 10 to 15 parts of raw cattail pollen and 10 to 20 parts of spreading hedyotis herb.
9. A Chinese medicinal preparation, characterized in that, is prepared from the Chinese medicinal composition of any one of claims 1 to 8 and pharmaceutically acceptable auxiliary materials;
preferably, the dosage form of the traditional Chinese medicine preparation comprises tablets, granules, pills, powder, paste, capsules, granules or powder.
10. The use of the composition of any one of claims 1 to 8 for the preparation of any one of the following medicaments;
1) A medicine for preventing and treating postoperative recurrence and metastasis of gastric cancer;
2) A medicament for improving clinical symptoms of a patient after gastric cancer surgery, wherein the clinical symptoms comprise at least one of chilliness, hypodynamia, anorexia, emaciation, gastroesophageal reflux, abdominal distension, abdominal pain, diarrhea, constipation and dumping syndrome;
3) Medicine for improving the life quality of patients after gastric cancer operation.
CN202210867484.4A 2022-07-22 2022-07-22 Traditional Chinese medicine composition for gastric cancer postoperative and application thereof Active CN115317583B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210867484.4A CN115317583B (en) 2022-07-22 2022-07-22 Traditional Chinese medicine composition for gastric cancer postoperative and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210867484.4A CN115317583B (en) 2022-07-22 2022-07-22 Traditional Chinese medicine composition for gastric cancer postoperative and application thereof

Publications (2)

Publication Number Publication Date
CN115317583A true CN115317583A (en) 2022-11-11
CN115317583B CN115317583B (en) 2023-09-29

Family

ID=83918677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210867484.4A Active CN115317583B (en) 2022-07-22 2022-07-22 Traditional Chinese medicine composition for gastric cancer postoperative and application thereof

Country Status (1)

Country Link
CN (1) CN115317583B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108635550A (en) * 2018-08-20 2018-10-12 江苏省中医院 A kind of pharmaceutical composition that treating gastric cancer and its application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108635550A (en) * 2018-08-20 2018-10-12 江苏省中医院 A kind of pharmaceutical composition that treating gastric cancer and its application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘南梅: "抗癌汤治疗胃癌术后临床观察", 中医现代药物应用, vol. 4, no. 9, pages 160 - 161 *
张乙等: "李杰病证结合辨治胃癌经验", 中国中医基础医学杂志, vol. 24, no. 11, pages 1639 - 1641 *
李杰: "胃癌的中西医结合治疗-广安门医院李杰教授", pages 1 - 25, Retrieved from the Internet <URL:https://ishare.iask.sina.com.cn/f/a5TpWf8Fmn.html> *
陈吉全等: "庞景三教授运用黄芪-党参-三棱-莪术药串经验", 中医研究, vol. 25, no. 9, pages 40 - 42 *

Also Published As

Publication number Publication date
CN115317583B (en) 2023-09-29

Similar Documents

Publication Publication Date Title
CN102284049A (en) Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof
CN101716318B (en) Traditional Chinese medicine preparation for treating tumor of digestive system
CN104940784B (en) A kind of Chinese medicine composition for treating chronic gastritis
CN103341092A (en) Preparation method of powder for treating atrophic vaginitis
CN105233188A (en) Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition
CN108938722A (en) A kind of intelligence system emplastrum and preparation method thereof for treating various constipation
CN100522237C (en) Anticancer soft capsule and its preparation process
CN115317583B (en) Traditional Chinese medicine composition for gastric cancer postoperative and application thereof
CN100509041C (en) Stomach-clearing pill
CN103316175A (en) Traditional Chinese medicine powder, and preparation method and application thereof
CN103301353A (en) Pharmaceutical composition for treating atrophic vaginitis
CN103520623B (en) Traditional Chinese medicine preparation used for treating gastric ulcer
CN102091262B (en) Antidiarrheal powder
CN104998140A (en) Traditional Chinese medicine preparation for treating chronic gastric ulcer
CN104547819A (en) Traditional Chinese medicine for treating spleen-stomach deficiency type stomach cancer and preparation method thereof
CN108434420A (en) A kind of Chinese medicine preparation for treating post operative colo-rectal cancer diarrhea
CN116747274B (en) Traditional Chinese medicine composition and preparation for treating gastroesophageal reflux disease with syndrome of liver-stomach stagnation heat and application of traditional Chinese medicine composition and preparation
CN101940643B (en) Medicament for treating gastric cancer and esophagus cancer
CN108186742B (en) Traditional Chinese medicine composition for treating constipation and preparation method thereof
CN105796676A (en) Pills for effectively treating fatty liver
CN106729543A (en) A kind of Chinese medicine for treating IBS
CN115364186A (en) Traditional Chinese medicine composition for esophageal cancer postoperation and application thereof
CN104984305B (en) A kind of Chinese medicine composition for treating chronic cholecystitis
CN117883536A (en) Traditional Chinese medicine composition for treating intestinal inflammation and cancer transformation diseases and application thereof
CN104784509A (en) Traditional Chinese medicine preparation for improving immunity of malignant tumor patient

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant